Refine
Year of publication
Document Type
- Article (5144)
- Doctoral Thesis (1479)
- Part of Periodical (210)
- Conference Proceeding (164)
- Preprint (164)
- Book (85)
- Contribution to a Periodical (63)
- Review (38)
- Working Paper (22)
- Part of a Book (17)
Language
Is part of the Bibliography
- no (7406) (remove)
Keywords
- inflammation (80)
- COVID-19 (58)
- SARS-CoV-2 (48)
- apoptosis (38)
- glioblastoma (38)
- Inflammation (37)
- cancer (37)
- breast cancer (34)
- autophagy (29)
- prostate cancer (27)
Institute
- Medizin (7406) (remove)
In einer prospektiven Studie wurden 68 Patienten mit Ersatz des vorderen und/oder hinteren Kreuzbands 2, 12, 24 Wochen, 1, 1,5 und 2 Jahre postoperativ kontrastmittelunterstützt magnetresonanztomographisch und klinisch untersucht, insgesamt wurden 160 MR-Untersuchungen durchgeführt. Sagittale, parasagittale und koronale Bilder wurden nativ mittels T1- und T2 gewichteter Spin Echo (SE) und Turbospinecho- (TSE) Sequenzen und nach Kontrastmittelgabe mit T1- und FS-Sequezen akquiriert. Die Resultate wurden mit den klinischen Untersuchungsergebnissen verglichen. Die Kriterien der MR-Auswertung umfassten die Morphologie, Signalintensität, das Kontrastmittelaufnahmeverhalten des Transplantates und Sekundärzeichen und der Vergleich mit den klinischen Untersuchungen einschließlich Stabilitäts- und Funktionstests entsprechend der Scores nach IKDC, OAK und Lysholm. Zwei Wochen postoperativ zeigten alle Kreuzbandtransplantate ein homogenes niedriges Signal in den T1 und T2 gewichteten SE Sequenzen, eine Unterscheidung zu den Signalen normaler Kreuzbänder sowie der verbliebenen Patellarsehne war nicht möglich. Innerhalb des ersten postoperativen Jahres konnte bei allen Patienten eine kontinuierliche Zunahme der Signalintensität und damit Inhomogenität des Bandersatzes beobachtet werden. Die Werte stiegen von 1,1a.u. auf 6,9 a.u. nach einem Jahr. Eine Beurteilung des Kreuzbandersatzes war nicht möglich. Im darauffolgenden postoperativen zweiten Jahr kam es zu einer Normalisierung des Signalintensitätsverhalten des Transplantates und somit zu einer besseren Abgrenzbarkeit (C/N=3,0). Alle Patienten wiesen postoperative einen unkomplizierten Verlauf mit klinisch stabilem Transplantat auf.
Introduction: Lumbosacral fixation is a common procedure in primary and revision spine surgery but leads to high biomechanical stress on adjacent segments and the SIJ, resulting in implant failure such as breakage and loosening and pain. This frequently results in further surgery. For patients showing clinical and radiological signs of SIJ affection/arthrosis who fail conservative therapy, transarticular lumbopelvic fusion via the SIJ may be considered. The Bedrock™ technique has been described as a new option for reinforced lumbopelvic fixation, fusing the SIJ with additional triangular titanium implants, thereby reducing biomechanical loads off the S2AI screws. We share our experiences with 19 patients treated with this technique since January 2019.
Materials and Methods: 19 patients suffering from persisting low back pain (LBP) with indication for reinforced lumbopelvic fixation and SIJ fusion were treated with reinforced lumboplevic fixation with S2AI screw and a triangular titanium implant. 14 cases were revisions. All surgeries were carried out by a single surgeon at a orthopedic university hospital. Data was gathered retrospectively.
Results: From 1/2019 - 9/2021 19 patients (11f, 8m) were treated with reinforced lumbopelvic fixation and SIJ fusion with a mean follow up of 18,2 months. Mean age 68 years (range 62-78y). Preop. walking distance was reduced to an average <100 m. Standard treatment involved S2AI screws and triangular titanium implants (SIBone, iFuse 3D™). 14 revision cases split into 5 low grade infections with screw loosening, 3 cases with rod breakage, 5 cases of painful lumbopelvic screw prominence, 7 cases with proximal junctional kyphosis, 2 cases with misplaced implants, 8 cases of poor bone mineral density. 5 patients without prior spine surgery. All patients were treated bilaterally using freehand technique. Average implant length was 65 mm. There were no intraoperative or implant associated adverse events (AE) or serious adverse events (SAE). Postoperative imaging demonstrated good implant positioning and function. All patients regained walking ability for distances > 1000 m and were satisfied with the result. All patients reported significant reduction of SIJ pain.
Conclusion: We report results of 19 patients with a reinforced lumbopelvic fixation and fusion by S2AI screws augmented by one parallelly placed triangular titanium implant fusing the SIJ bilaterally with a mean follow-up of 18.2 months. Intra- and postoperatively we experienced no implant associated adverse event. Patients regained significant walking ability and significant reduction of SIJ pain. Radiologically no signs of implant loosening or failure were detected at the end of follow-up. Our results demonstrate a safe and efficacious surgical technique for reinforced lumbopelvic fixation with fusion of SIJ with significant improvement of the health care related quality of life. Further studies need to be conducted in order to obtain additional evidence.
Prostaglandin (PG) E2 (PGE2) plays a predominant role in promoting colorectal carcinogenesis. The biosynthesis of PGE2 is accomplished by conversion of the cyclooxygenase (COX) product PGH2 by several terminal prostaglandin E synthases (PGES). Among the known PGES isoforms, microsomal PGES type 1 (mPGES-1) and type 2 (mPGES-2) were found to be overexpressed in colorectal cancer (CRC); however, the role and regulation of these enzymes in this malignancy are not yet fully understood. Here, we report that the cyclopentenone prostaglandins (CyPGs) 15-deoxy-Δ12,14-PGJ2 and PGA2 downregulate mPGES-2 expression in the colorectal carcinoma cell lines Caco-2 and HCT 116 without affecting the expression of any other PGES or COX. Inhibition of mPGES-2 was subsequently followed by decreased microsomal PGES activity. These effects were mediated via modulation of the cellular thiol-disulfide redox status but did not involve activation of the peroxisome proliferator-activated receptor γ or PGD2 receptors. CyPGs had antiproliferative properties in vitro; however, this biological activity could not be directly attributed to decreased PGES activity because it could not be reversed by adding PGE2. Our data suggest that there is a feedback mechanism between PGE2 and CyPGs that implicates mPGES-2 as a new potential target for pharmacological intervention in CRC.
CONTENTS: Keynote Address and Invited Plenary Lectures Symposia Debates and Panels Oral Presentations and Specific Topics Poster Presentations Workshop Presentations Case Study Presentations and Media Presentations Symposien Workshops
Objectives: The authors sought to evaluate the performance of the Ranger paclitaxel-coated balloon versus uncoated balloon angioplasty for femoropopliteal lesions at 12 months.
Background: Drug-coated balloons (DCBs) are a promising endovascular treatment option for peripheral artery disease of the femoropopliteal segment, and each unique device requires dedicated clinical study.
Methods: The prospective, randomized RANGER SFA (Comparison of the Ranger™ Paclitaxel-Coated PTA Balloon Catheter and Uncoated PTA Balloons in Femoropopliteal Arteries) study (NCT02013193) enrolled 105 patients with symptomatic lower limb ischemia (Rutherford category 2 to 4) and stenotic lesions in the nonstented femoropopliteal segment at 10 European centers. Seventy-one patients (mean age 68 ± 8 years, n = 53 men) were enrolled in the Ranger DCB arm, and 34 patients (mean age 67 ± 9 years, n = 23 men) were assigned to the control group. Twelve-month analysis included patency, safety, and clinical outcomes and quality-of-life assessments.
Results: The DCB group had a greater primary patency rate at 12 months (Kaplan-Meier estimate 86.4% vs. 56.5%), with a significantly longer time to patency failure (log-rank p < 0.001). The estimated freedom from target lesion revascularization rate was 91.2% in the DCB group and 69.9% in the control group at 12 months, with a significantly longer time to reintervention (p = 0.010). No target limb amputations or device-related deaths occurred in either group.
Conclusions: Twelve-month results show that patency was maintained longer after Ranger DCB treatment than after conventional balloon angioplasty, and this result was associated with a low revascularization rate and good clinical outcomes.
Cytochrome P450-derived epoxyeicosatrienoic acids (EETs) stimulate endothelial cell proliferation and angiogenesis. In this study, we investigated the involvement of the forkhead box, class O (FOXO) family of transcription factors and their downstream target p27Kip1 in EET-induced endothelial cell proliferation. Incubation of human umbilical vein endothelial cells with 11,12-EET induced a time- and dose-dependent decrease in p27Kip1 protein expression, whereas p21Cip1 was not significantly affected. This effect on p27Kip1 protein was associated with decreased mRNA levels as well as p27Kip1 promoter activity. 11,12-EET also stimulated the time-dependent phosphorylation of Akt and of the forkhead factors FOXO1 and FOXO3a, effects prevented by the phosphatidylinositol 3-kinase inhibitor LY 294002. Transfection of endothelial cells with either a dominant-negative or an “Akt-resistant”/constitutively active FOXO3a mutant reversed the 11,12-EET-induced down-regulation of p27Kip1, whereas transfection of a constitutive active Akt decreased p27Kip1 expression independently of the presence or absence of 11,12-EET. To determine whether these effects are involved in EET-induced proliferation, endothelial cells were transfected with the 11,12-EET-generating epoxygenase CYP2C9. Transfection of CYP2C9 elicited endothelial cell proliferation and this effect was inhibited in cells co-transfected with CYP2C9 and either a dominant-negative Akt or constitutively active FOXO3a. Reducing FOXO expression using RNA interference, on the other hand, attenuated p27Kip1 expression and stimulated endothelial cell proliferation. These results indicate that EET-induced endothelial cell proliferation is associated with the phosphatidylinositol 3-kinase/Akt-dependent phosphorylation and inactivation of FOXO factors and the subsequent decrease in expression of the cyclin-dependent kinase inhibitor p27Kip1.
In the systemic circulation, 11,12-epoxyeicosatrienoic acid (11,12-EET) elicits nitric oxide (NO)- and prostacyclin-independent vascular relaxation, partially through the activation of large conductance Ca2+-activated potassium (BK) channels. However, in the lung 11,12-EET contributes to hypoxia-induced pulmonary vasoconstriction. Since pulmonary artery smooth muscle cells also express BK channels, we assessed the consequences of BKβ1 subunit deletion on pulmonary responsiveness to 11,12-EET as well as to acute hypoxia. In buffer-perfused mouse lungs, hypoxia increased pulmonary artery pressure and this was significantly enhanced in the presence of NO synthase (NOS) and cyclooxygenase (COX) inhibitors. Under these conditions the elevation of tissue EET levels using an inhibitor of the soluble epoxide hydrolase (sEH-I), further increased the hypoxic contraction. Direct administration of 11,12-EET also increased pulmonary artery pressure, and both the sEH-I and 11,12-EET effects were prevented by iberiotoxin and absent in BKβ1−/− mice. In pulmonary artery smooth muscle cells treated with NOS and COX inhibitors and loaded with the potentiometric dye, di-8-ANEPPS, 11,12-EET induced depolarization while the BK channel opener NS1619 elicited hyperpolarization indicating there was no effect of the EET on classical plasma membrane BK channels. In pulmonary artery smooth muscle cells a subpopulation of BK channels is localized in mitochondria. In these cells, 11,12-EET elicited an iberiotoxin-sensitive loss of mitochondrial membrane potential (JC-1 fluorescence) leading to plasma membrane depolarization, an effect not observed in BKβ1−/− cells. Mechanistically, stimulation with 11,12-EET time-dependently induced the association of the BK α and β1 subunits. Our data indicate that in the absence of NO and prostacyclin 11,12-EET contributes to pulmonary vasoconstriction by stimulating the association of the α and β1 subunits of mitochondrial BK channels. The 11,12-EET-induced activation of BK channels results in loss of the mitochondrial membrane potential and depolarization of the pulmonary artery smooth muscle cells.
Epoxyeicosatrienoic acids (EET) facilitate regeneration in different tissues, and their benefit in dermal wound healing has been proven under normal conditions. In this study, we investigated the effect of 11,12 EET on dermal wound healing in diabetes. We induced diabetes by i.p. injection of streptozotocin 2 weeks prior to wound creation on the dorsal side of the mouse ear. 11,12 EET was applied every second day on the wound, whereas the control groups received only solvent. Epithelialization was monitored every second day intravitally up to wound closure. Wounds were stained for VEGF, CD31, TGF-β, TNF-α, SDF-1α, NF-κB, and Ki-67, and fibroblasts were counted after hematoxylin-eosin stain on days 3, 6, 9, and 16 after wounding. After induction of diabetes, wounds closed on day 13.00 ± 2.20 standard deviation (SD). Local 11,12 ETT application improved wound closure significantly to day 8.40 ± 1.39 SD. EET treatment enhanced VEGF and CD31 expression in wounds on day 3. It also seemed to raise TNF-α level on all days investigated as well as TGF-β level on days 3 and 6. A decrease in NF-κB could be observed on days 9 and 16 after EET application. The latter findings were not significant. SDF-1α expression was not influenced by EET application, and Ki-67 was significantly less in the EET group on day 9 after EET application. The number of fibroblasts was significantly increased on day 9 after the 11,12 EET application. 11,12 EET improve deteriorated wound healing in diabetes by enhancing neoangiogenesis, especially in the early phase of wound healing. Furthermore, they contribute to the dissolution of the initial inflammatory reaction, allowing the crucial transition from the inflammatory to proliferative phase in wound healing.
Introduction: Epoxyeicosatrienoic acids (EETs) are able to enhance angiogenesis and regulate inflammation that is especially important in wound healing under ischemic conditions. Thus, we evaluated the effect of local EET application on ischemic wounds in mice.
Methods: Ischemia was induced by cautherization of two of the three supplying vessels to the mouse ear. Wounding was performed on the ear three days later. Wounds were treated either with 11,12 or 14,15 EET and compared to untreated control and normal wounds. Epithelialization was measured every second day. VEGF, TNF-α, TGF-β, matrix metalloproteinases (MMP), tissue inhibitors of metalloproteinases (TIMP), Ki67, and SDF-1α were evaluated immunohistochemically in wounds on day 3, 6, and 9.
Results: Ischemia delayed wound closure (12.8 days ± 1.9 standard deviation (SD) for ischemia and 8.0 days ± 0.94 SD for control). 11,12 and14,15 EET application ameliorated deteriorated wound healing on ischemic ears (7.6 ± 1.3 SD for 11,12 EET and 9.2 ± 1.4 SD for 14,15 EET). Ischemia did not change VEGF, TNF-α, TGF-β, SDF-1α, TIMP, MMP7 or MMP9 level significantly compared to control. Local application of 11,12 as well as 14,15 EET induced a significant elevation of VEGF, TGF-β, and SDF-1α expression as well as proliferation during the whole phase of wound healing compared to control and ischemia alone.
Conclusion: In summary, EET improve impaired wound healing caused by ischemia as they enhance neovascularization and alter inflammatory response in wounds. Thus elevating lipid mediator level as 11,12 and 14,15 EET in wounds might be a successful strategy for amelioration of deranged wound healing under ischemia.